Medicine and Dentistry
Pancreas Cancer
100%
Neoplasm
86%
Surgery
82%
Hepatocellular Carcinoma
63%
Abdominal Cancer
54%
Hepatectomy
53%
Pancreaticoduodenectomy
50%
Recurrent Disease
50%
Malignant Neoplasm
39%
Overall Survival
37%
Pancreas Adenocarcinoma
32%
Prognostic Factor
30%
Metastatic Carcinoma
27%
Chemotherapy
26%
Hepatic Portal Vein
24%
Pancreas Fistula
23%
Pancreatectomy
23%
Distal Pancreatectomy
23%
Multivariate Analysis
22%
Esophagectomy
21%
Esophageal Squamous Cell Carcinoma
21%
Liver Metastasis
20%
Lymph Node Metastasis
20%
Gastrectomy
19%
Computer Assisted Tomography
18%
Messenger RNA
18%
Cancer Cell
17%
Esophagus
16%
Intraductal Papillary Mucinous Tumor
15%
Gemcitabine
15%
Adjuvant Chemotherapy
15%
Lymphocyte
15%
Bleeding
15%
Peritoneum Metastasis
14%
Cancer
14%
Cholangiocarcinoma
13%
Disease
13%
Postoperative Complication
13%
Adenocarcinoma
13%
Recurrence Free Survival
13%
Esophageal Cancer
12%
Disease Free Survival
12%
Lymph Node
12%
Biological Marker
11%
Colorectal Carcinoma
11%
Hazard Ratio
11%
Survival Rate
11%
Surgical Anastomosis
11%
Tail
11%
Pancreatic Surgery
11%
Carcinoma
10%
Retroperitoneal Lymph Node Dissection
10%
Odds Ratio
10%
Paclitaxel
9%
Chemoradiotherapy
9%
Artery
9%
Cytotechnology
9%
Ulcerative Colitis
8%
Splenic Vein
8%
Predictive Factor
8%
Platelet
8%
Skeletal Muscle
8%
Univariate Analysis
8%
Nutrition Assessment
7%
Melanoma Antigen
7%
Fluorodeoxyglucose
7%
Randomized Controlled Trial
7%
Diagnosis
7%
Breast Cancer
7%
Laparoscopic Surgery
7%
Mesenchymal-Epithelial Transition
7%
Long Term Survival
7%
Magnetic Resonance Imaging
7%
Pancreas Islet Cell Tumor
7%
Operation Duration
7%
Retrospective Study
7%
Pancreatic Duct
7%
Median Survival Time
7%
Head Cancer
7%
Neoadjuvant Therapy
7%
Tumor Progression
7%
Pancreaticojejunostomy
6%
Squamous Cell Carcinoma
6%
C Reactive Protein
6%
Elderly Patient
6%
Superior Mesenteric Artery
6%
Cancer Surgery
6%
Methylation
6%
Stenosis
6%
Jejunum
6%
Positron Emission Tomography
6%
Embolization
6%
Neutrophil
6%
Colorectal Liver Metastasis
6%
Tumor Marker
6%
Indocyanine Green
6%
Adverse Event
5%
Duodenum
5%
Pancreas Carcinoma
5%
Body Mass Index
5%
Keyphrases
Hepatocellular Carcinoma
88%
Pancreatic Cancer
84%
Gastric Cancer
56%
Pancreaticoduodenectomy
49%
Tumor
49%
Overall Survival
34%
Esophageal Squamous Cell Carcinoma
31%
Resection
26%
Pancreatic Ductal Adenocarcinoma
26%
Hepatic Resection
24%
Resectable Pancreatic Cancer
23%
Multivariate Analysis
22%
Prognostic Factors
20%
Pancreatectomy
19%
Chemotherapy
18%
Peritoneal Metastasis
18%
Pancreas
18%
Poor Prognosis
17%
Japan
17%
Independent Prognostic Factor
16%
Lymph Node Metastasis
16%
Curative Resection
16%
Intraductal Papillary mucinous Neoplasm
16%
Distal Pancreatectomy
16%
Gemcitabine
14%
Computed Tomography
14%
Older Men
14%
Hepatectomy
14%
Disease-free Survival
14%
Postoperative Pancreatic Fistula
13%
Colorectal Liver Metastases
13%
Confidence Interval
13%
Liver
13%
Postoperative Complications
13%
Colorectal Cancer
12%
Hazard Ratio
12%
Adjuvant Chemotherapy
12%
Pancreatic Fistula
12%
Malignant Phenotype
12%
Recurrence-free Survival
12%
After Surgery
12%
Postoperative Day
12%
Risk Factors
11%
Odds Ratio
11%
Stomach
11%
Epithelial-to-mesenchymal Transition
10%
Esophageal Cancer
10%
Portal Vein
10%
Liver Metastasis
10%
Older Women
10%
Oncolytic Herpes Simplex Virus (oHSV)
10%
Metastasis
10%
Prognosis Prediction
9%
Tumor Suppressor
9%
Prognostic Significance
9%
Phase II Study
9%
Expression Level
9%
Array Analysis
9%
Ulcerative Colitis
9%
Long-term Survival
9%
Tumor Suppressor Gene
9%
Overexpression
9%
Prognostic Impact
8%
Splenic Vein
8%
Bevacizumab
8%
Promoter Methylation
8%
Advanced Gastric Cancer
8%
Gastric Cancer Cell Lines
8%
Triple Combination Array
8%
Peritoneal Dissemination
8%
Hepatocellular Carcinoma Cells
8%
Gemcitabine Plus Nab-paclitaxel
8%
Pathological Findings
8%
Hepatic Metastasis
8%
Gastric Tissue
8%
Peritoneal Cytology
7%
Gastric Cancer Cells
7%
Japan Pancreas Society
7%
Postoperative Outcomes
7%
Pancreatic Head
7%
Antitumor Effect
7%
Patient Survival
7%
Pancreatic Resection
7%
Postoperative Prognosis
7%
Pancreatic Surgery
7%
Univariate Analysis
7%
Conversion Surgery
7%
Neoadjuvant Therapy
7%
Median Survival Time
7%
Malignancy
7%
Cluster of Differentiation 44 (CD44)
7%
In Cancer
7%
Neoadjuvant Chemoradiotherapy (nCRT)
7%
No Significant Difference
7%
Cancer Patients
7%
Metastatic Colorectal Cancer (mCRC)
7%
Pancreatic Head Cancer
7%
Tumor Size
7%
Propensity Score Analysis
7%
Surgical Resection
6%